Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Pharmacyclics Inc.
Headquarters: Sunnyvale, CA, United States of America
Website: N/A
Year Founded: 1991
Status: Acquired
BioCentury | May 31, 2024
Product Development
Summit reaps benefit of Akeso deal as bispecific beats Keytruda head-to-head in China-only NSCLC study
Partners announce PFS benefit from monotherapy head-to-head. Summit’s Phase III program outside China adds chemotherapy to the mix
BioCentury | Dec 7, 2023
Deals
AbbVie sees Cerevel’s antipsychotic as ‘best-in-class’ driver of $8.7B deal
Again investing outside immunology, pharma sees differentiation in potential competitor with Karuna’s registrational schizophrenia therapy
BioCentury | Aug 29, 2023
Finance
Where is the sweet spot for M&A?
Back to School 2023: An analysis of biotech takeouts by market cap size
BioCentury | Apr 19, 2023
Finance
Gilde seeking value in bear market with focus on POC, ‘dynamic’ bets on public biotechs
Firm is latest top-tier EU VC to raise new fund, hitting €600M
BioCentury | Jan 13, 2023
Finance
Surviving a year of the haves and have-nots
BioCentury’s 2023 Financial Markets Preview
BioCentury | Dec 7, 2022
Deals
Akeso deal marks Summit’s transition to Pharmacyclics 2.0
Led by Bob Duggan and Maky Zanganeh, small cap paying $500M up front to get U.S.-EU-Japan rights to bispecific ivonescimab
BioCentury | Aug 2, 2022
Management Tracks
Mackison named CEO at Vico
Plus Arvinas hires Northcott as CCO, Manion joins Aclaris and updates from AnHeart, Gracell, Find and more
BioCentury | Dec 9, 2021
Finance
F-Prime, Atlas back K36 with $30M to advance MM candidate
Newly launched K36 in-licensed potential first-in-class therapy from Novartis for multiple myeloma subset
BioCentury | Mar 28, 2021
Finance
Launched by Pharmacyclics vets, preclinical cancer start-up Biomea Fusion seeks short path to IPO
Menin inhibitor moving toward clinic three months after series A
BioCentury | Dec 9, 2019
Company News
With $2.7B ArQule buyout, Merck is latest pharma to jump into Btk race
Items per page:
1 - 10 of 447